Premium
Inhibition of extracellular signal‐regulated kinase1/2 activity of the breast cancer cell line MDA‐MB‐231 leads to major alterations in the pattern of protein expression
Author(s) -
Seddighzadeh Maria,
Linder Stig,
Shoshan Maria C.,
Auer Gert,
Alaiya Ayodele A.
Publication year - 2000
Publication title -
electrophoresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 158
eISSN - 1522-2683
pISSN - 0173-0835
DOI - 10.1002/1522-2683(20000701)21:13<2737::aid-elps2737>3.0.co;2-2
Subject(s) - mapk/erk pathway , kinase , protein kinase a , extracellular , signal transduction , biology , microbiology and biotechnology , cell growth , mitogen activated protein kinase kinase , cancer research , biochemistry
Biochemical and genetic strategies have implied that abberant signaling in the extracellular signal‐regulated kinase (ERK)/mitogen‐activated protein (MAP) kinase pathway contributes significantly to transformed phenotypes. Using PD98059, an inhibitor of the ERK‐kinase MEK1, we have here assessed the effects of ERK inhibition on the pattern of protein expression in the metastatic human breast cancer cell line MDA‐MB‐231. At a concentration of inhibitor which did not significantly affect cell growth, PD98059 induced large changes in the expression of MDA‐MB‐231 polypeptides. The majority of these changes were due to decreased expression of low‐abundant proteins. Decreases of more abundant proteins such as glutathione‐ S ‐transferase π, hsp80 and hsp100 were also recorded. The levels of a few proteins increased, among them cytokeratin 8. We conclude that PD98059 treatment of MDA‐MB‐231 cells induces large changes in protein expression.